Read More

Standard BioTools And SomaLogic To Combine In All-Stock Merger Creating A Diversified Leader In Life Sciences Tools; Standard BioTools Shareholders Will Own ~43% Of The Combined Co, And SomaLogic Shareholders Will Own ~57% Of The Combined Co

Activates Standard BioTools' strategy to unlock value in underserved portion of $100 billion industry Establishes leading platform of multi-omic technologies with the highest throughput and highest data quality to

LAB

Read More

SomaLogic Expands Agreement With Novo Nordisk To 2025, Will Expand Its Use Of The SomaScan Proteomics Platform In Drug R&D Novo Nordisk Will Also Use SomaLogic’s SomaSignal Tests For Investigations Into Cardiometabolic And Other Diseases

SomaLogic, Inc., a leader in proteomics technology, announced today that it is extending its collaborative agreement with global healthcare innovator, Novo Nordisk. As part of the agreement, which now extends into the

NVO